SFI
BEAM icon

Susquehanna Fundamental Investments’s Beam Therapeutics BEAM Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-21,025
Closed -$583K – 502
2025
Q4 		$583K Sell
21,025
-1,811
-8% -$46.2K 0.02% 411
2025
Q3 		$554K Sell
22,836
-14,769
-39% -$294K 0.02% 424
2025
Q2 		$640K Sell
37,605
-36,253
-49% -$631K 0.02% 513
2025
Q1 		$1.44M Buy
73,858
+21,133
+40% +$554K 0.02% 604
2024
Q4 		$1.31M Buy
+52,725
New +$1.35M 0.02% 638

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Susquehanna Fundamental Investments's BEAM Position: Q1 2026 in Review

Susquehanna Fundamental Investments sold out of Beam Therapeutics (BEAM) in Q1 2026, closing a stake of 21,025 shares — an estimated $583K sold.

Susquehanna Fundamental Investments first reported a position in BEAM in Q4 2024 and held it in 5 quarters. The position peaked at $1.44M in Q1 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Susquehanna Fundamental Investments reported no remaining Beam Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 21,025 Beam Therapeutics shares in Q1 2026, an estimated $583K.
  • Susquehanna Fundamental Investments first reported a position in Beam Therapeutics in Q4 2024 and held it in 5 quarters.
  • Susquehanna Fundamental Investments's Beam Therapeutics position peaked at $1.44M in Q1 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2026, filed 15 May 2026.